Intra-Cellular Therapies Shares Outstanding 2013-2022 | ITCI
Intra-Cellular Therapies shares outstanding history from 2013 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- Intra-Cellular Therapies shares outstanding for the quarter ending March 31, 2022 were 0.093B, a 14.4% increase year-over-year.
- Intra-Cellular Therapies 2021 shares outstanding were 0.081B, a 15.47% increase from 2020.
- Intra-Cellular Therapies 2020 shares outstanding were 0.07B, a 27.51% increase from 2019.
- Intra-Cellular Therapies 2019 shares outstanding were 0.055B, a 0.87% increase from 2018.
Intra-Cellular Therapies Annual Shares Outstanding
(Millions of Shares) |
| 2021 |
81 |
| 2020 |
70 |
| 2019 |
55 |
| 2018 |
55 |
| 2017 |
46 |
| 2016 |
43 |
| 2015 |
36 |
| 2014 |
29 |
| 2013 |
17 |
| 2012 |
6 |
Intra-Cellular Therapies Quarterly Shares Outstanding
(Millions of Shares) |
| 2022-03-31 |
93 |
| 2021-12-31 |
81 |
| 2021-09-30 |
81 |
| 2021-06-30 |
81 |
| 2021-03-31 |
81 |
| 2020-12-31 |
70 |
| 2020-09-30 |
70 |
| 2020-06-30 |
66 |
| 2020-03-31 |
65 |
| 2019-12-31 |
55 |
| 2019-09-30 |
55 |
| 2019-06-30 |
55 |
| 2019-03-31 |
55 |
| 2018-12-31 |
55 |
| 2018-09-30 |
55 |
| 2018-06-30 |
55 |
| 2018-03-31 |
55 |
| 2017-12-31 |
46 |
| 2017-09-30 |
43 |
| 2017-06-30 |
43 |
| 2017-03-31 |
43 |
| 2016-12-31 |
43 |
| 2016-09-30 |
43 |
| 2016-06-30 |
43 |
| 2016-03-31 |
43 |
| 2015-12-31 |
36 |
| 2015-09-30 |
35 |
| 2015-06-30 |
35 |
| 2015-03-31 |
31 |
| 2014-12-31 |
29 |
| 2014-09-30 |
29 |
| 2014-06-30 |
29 |
| 2014-03-31 |
26 |
| 2013-12-31 |
17 |
| 2013-09-30 |
18 |
| 2013-06-30 |
15 |
| 2013-03-31 |
15 |
| 2012-12-31 |
|
| 2012-09-30 |
6 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$5.373B |
$0.084B |
|
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
|
